vs

Side-by-side financial comparison of Emerson Electric (EMR) and Linde plc (LIN). Click either name above to swap in a different company.

Linde plc is the larger business by last-quarter revenue ($8.8B vs $4.6B, roughly 1.9× Emerson Electric). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs 3.0%). Emerson Electric produced more free cash flow last quarter ($694.0M vs $898.0K). Over the past eight quarters, Linde plc's revenue compounded faster (3.1% CAGR vs -0.6%).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

EMR vs LIN — Head-to-Head

Bigger by revenue
LIN
LIN
1.9× larger
LIN
$8.8B
$4.6B
EMR
Growing faster (revenue YoY)
LIN
LIN
+5.2% gap
LIN
8.2%
3.0%
EMR
More free cash flow
EMR
EMR
$693.1M more FCF
EMR
$694.0M
$898.0K
LIN
Faster 2-yr revenue CAGR
LIN
LIN
Annualised
LIN
3.1%
-0.6%
EMR

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
EMR
EMR
LIN
LIN
Revenue
$4.6B
$8.8B
Net Profit
$618.0M
Gross Margin
53.1%
48.5%
Operating Margin
27.8%
Net Margin
13.5%
Revenue YoY
3.0%
8.2%
Net Profit YoY
43.7%
EPS (diluted)
$1.10
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EMR
EMR
LIN
LIN
Q2 26
$4.6B
Q1 26
$4.3B
$8.8B
Q4 25
$4.3B
$8.8B
Q3 25
$4.9B
$8.6B
Q2 25
$4.6B
$8.5B
Q1 25
$4.4B
$8.1B
Q4 24
$4.2B
$8.3B
Q3 24
$4.6B
$8.4B
Net Profit
EMR
EMR
LIN
LIN
Q2 26
$618.0M
Q1 26
$606.0M
Q4 25
$605.0M
$1.5B
Q3 25
$637.0M
$1.9B
Q2 25
$586.0M
$1.8B
Q1 25
$485.0M
$1.7B
Q4 24
$585.0M
$1.7B
Q3 24
$996.0M
$1.6B
Gross Margin
EMR
EMR
LIN
LIN
Q2 26
53.1%
Q1 26
53.2%
48.5%
Q4 25
53.2%
Q3 25
51.9%
Q2 25
52.6%
Q1 25
53.5%
Q4 24
53.5%
Q3 24
51.3%
Operating Margin
EMR
EMR
LIN
LIN
Q2 26
Q1 26
27.8%
Q4 25
17.8%
23.0%
Q3 25
16.4%
27.5%
Q2 25
16.1%
27.7%
Q1 25
14.2%
26.9%
Q4 24
18.6%
27.4%
Q3 24
14.7%
25.0%
Net Margin
EMR
EMR
LIN
LIN
Q2 26
13.5%
Q1 26
13.9%
Q4 25
13.9%
17.5%
Q3 25
13.1%
22.4%
Q2 25
12.9%
20.8%
Q1 25
10.9%
20.6%
Q4 24
14.0%
20.8%
Q3 24
21.6%
18.5%
EPS (diluted)
EMR
EMR
LIN
LIN
Q2 26
$1.10
Q1 26
$1.07
$3.98
Q4 25
$1.07
$3.28
Q3 25
$1.12
$4.09
Q2 25
$1.04
$3.73
Q1 25
$0.86
$3.51
Q4 24
$1.02
$3.61
Q3 24
$1.74
$3.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EMR
EMR
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$1.8B
$4.0B
Total DebtLower is stronger
$13.4B
$24.7B
Stockholders' EquityBook value
$20.3B
$40.1B
Total Assets
$42.1B
$86.3B
Debt / EquityLower = less leverage
0.66×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EMR
EMR
LIN
LIN
Q2 26
$1.8B
Q1 26
$1.7B
$4.0B
Q4 25
$5.1B
Q3 25
$4.5B
Q2 25
$4.8B
Q1 25
$5.3B
Q4 24
$4.8B
Q3 24
$5.2B
Total Debt
EMR
EMR
LIN
LIN
Q2 26
$13.4B
Q1 26
$13.4B
$24.7B
Q4 25
$7.6B
$20.7B
Q3 25
$8.9B
$18.6B
Q2 25
$8.3B
$19.7B
Q1 25
$8.2B
$17.6B
Q4 24
$6.6B
$15.3B
Q3 24
$7.7B
$17.5B
Stockholders' Equity
EMR
EMR
LIN
LIN
Q2 26
$20.3B
Q1 26
$20.3B
$40.1B
Q4 25
$20.3B
$38.2B
Q3 25
$20.3B
$38.6B
Q2 25
$19.9B
$38.5B
Q1 25
$19.2B
$38.0B
Q4 24
$20.5B
$38.1B
Q3 24
$21.6B
$39.2B
Total Assets
EMR
EMR
LIN
LIN
Q2 26
$42.1B
Q1 26
$41.9B
$86.3B
Q4 25
$41.9B
$86.8B
Q3 25
$42.0B
$86.0B
Q2 25
$42.5B
$86.1B
Q1 25
$42.0B
$82.7B
Q4 24
$42.6B
$80.1B
Q3 24
$44.2B
$82.5B
Debt / Equity
EMR
EMR
LIN
LIN
Q2 26
0.66×
Q1 26
0.66×
0.62×
Q4 25
0.37×
0.54×
Q3 25
0.44×
0.48×
Q2 25
0.42×
0.51×
Q1 25
0.42×
0.46×
Q4 24
0.32×
0.40×
Q3 24
0.36×
0.45×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EMR
EMR
LIN
LIN
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$694.0M
$898.0K
FCF MarginFCF / Revenue
15.2%
0.0%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.6B
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EMR
EMR
LIN
LIN
Q2 26
Q1 26
Q4 25
$699.0M
$3.0B
Q3 25
$3.1B
$2.9B
Q2 25
$1.1B
$2.2B
Q1 25
$241.0M
$2.2B
Q4 24
$777.0M
$2.8B
Q3 24
$3.3B
$2.7B
Free Cash Flow
EMR
EMR
LIN
LIN
Q2 26
$694.0M
Q1 26
$602.0M
$898.0K
Q4 25
$602.0M
$1.6B
Q3 25
$2.7B
$1.7B
Q2 25
$977.0M
$954.0M
Q1 25
$154.0M
$891.0M
Q4 24
$694.0M
$1.6B
Q3 24
$2.9B
$1.7B
FCF Margin
EMR
EMR
LIN
LIN
Q2 26
15.2%
Q1 26
13.9%
0.0%
Q4 25
13.9%
17.9%
Q3 25
54.9%
19.4%
Q2 25
21.5%
11.2%
Q1 25
3.5%
11.0%
Q4 24
16.6%
18.8%
Q3 24
63.1%
19.9%
Capex Intensity
EMR
EMR
LIN
LIN
Q2 26
4.0%
Q1 26
2.2%
Q4 25
2.2%
16.6%
Q3 25
8.9%
14.8%
Q2 25
2.0%
14.8%
Q1 25
2.0%
15.7%
Q4 24
2.0%
15.1%
Q3 24
9.1%
12.8%
Cash Conversion
EMR
EMR
LIN
LIN
Q2 26
Q1 26
Q4 25
1.16×
1.98×
Q3 25
4.86×
1.53×
Q2 25
1.83×
1.25×
Q1 25
0.50×
1.29×
Q4 24
1.33×
1.63×
Q3 24
3.35×
1.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons